> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lagevrio Misses Endpoint in Covid-19 Study
- URL: https://www.fdaweb.com/lagevrio-misses-endpoint-in-covid-19-study/
- Published: 2023-02-21T12:00:00.000Z
- Updated: 2026-09-14T18:16:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153823

Merck says a study of its Covid-19 drug Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of Covid-19 in those who were exposed to the virus by another in their household. In the company’s Phase 3 MOVe-AHEAD trial, the Lagevrio-treated group was 23.6% less likely than those who received placebo to develop Covid-19 through day 14, which failed to meet the primary endpoint.

Lagevrio is a nucleoside analog that inhibits SARS-CoV-2 replication by viral mutagenesis, and marketed under an emergency use authorization for treating adults with a current diagnosis of mild-to-moderate Covid-2019 who are at high risk for progression to severe disease, according to Merck. It intends to submit full results from the study at a future scientific meeting, or for publication in a medical journal.